Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Bibliographic Details
Main Authors: Cree, BAC, Bennett, JL, Kim, HJ, Weinshenker, BG, Pittock, SJ, Wingerchuk, DM, Fujihara, K, Paul, F, Cutter, GR, Marignier, R, Green, AJ, Aktas, O, Hartung, H-P, Lublin, FD, Drappa, J, Barron, G, Madani, S, Ratchford, JN, She, D, Cimbora, D, Katz, E
Format: Journal article
Language:English
Published: Elsevier 2019
Description
Summary:

Similar Items